久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

Catalog No.

KDB95602

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Detection method

Colorimetric

Precision

CV<20%

Sample type

Plasma, Serum

Assay type

Quantitative

Sensitivity

0.156 μg/ml

Range

0.31-5 μg/mL

Recovery

80-120%

Specifications

Gevokizumab

Alternative Names

XOMA 052, CAS: 1129435-60-4

Background

Gevokizumab (XOMA-052) was developed by XOMA Ltd., USA and represents a humanized IgG2kappa antibody. XOMA-052 binds to IL-1β with high affinity leading to reduced binding affinity of the cytokine to its signaling receptor. Since gevokizumab does not influence the affinity of IL-1β for its decoy and soluble inhibitory receptors the endogenous regulatory mechanisms involving the clearance and inhibitory receptors also contribute to the effect of the antibody [6]. In August 2012 the FDA granted orphan drug status to gevokizumab for the treatment of noninfectious intermediate uveitis, posterior uveitis, panuveitis, and chronic noninfectious anterior uveitis. A single intravenous injection of the substance was also shown to lead to complete resolution of intraocular inflammation in Beh?et’s uveitis.

Shipping

2-8 ℃

Note

For Research Use Only.

Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.

AntibodySystem由具有30多年蛋白抗體開(kāi)發(fā)經(jīng)驗(yàn)的 創(chuàng)立于法國(guó),專注于生命科學(xué)和生物制藥領(lǐng)域研究,總部位于法國(guó)斯特拉斯堡市。AntibodySystem自主開(kāi)發(fā)了高效、高產(chǎn)的真核重組表達(dá)系統(tǒng),利用該系統(tǒng)生產(chǎn)了高質(zhì)量的重組蛋白、抗體產(chǎn)品。目前產(chǎn)品包括藥物靶點(diǎn)蛋白以及對(duì)照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。


普健生物作為AntibodySystem在亞洲區(qū)授權(quán) ,致力于為廣大科研工作者提供 的產(chǎn)品服務(wù)。

如果您對(duì)我們的產(chǎn)品感興趣,請(qǐng)聯(lián)系027-65279366。

以上產(chǎn)品僅用于科研,產(chǎn)品信息以產(chǎn)品 為準(zhǔn)